SGLT-2 inhibitors in development for type 2 diabetes treatment

Review of Diabetic Studies

Volumn 8, Issue 3, 2011, Pages 348-354

  Bhartia, Mithun ^a   Tahrani, Abd A ^b,c   Barnett, Anthony H ^b,c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Glucose reabsorption; Kidney; Renal glucose; SGLT; Sodium glucose cotransporter; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; BLADDER CANCER; BLOOD PRESSURE; BREAST CANCER; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME INHIBITION; EVENING DOSAGE; FOLLOW UP; GENE MUTATION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IN VIVO STUDY; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84855992711     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2011.8.348     Document Type: Article

References (26)

1. Diabetes UK website, Reports and Statistics. http://www.diabetes.org.uk/Professionals/Publicationsreports-and-resources/Reports-statistics-and-casestudies/Reports/Diabetes-prevalence-2010. Accessed on July 1, 2011.
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011. 378(9785):31-40.
3. International Diabetes Federation. IDF diabetes atlas. http://www.diabetesatlas.org/book/export/html/36.
4. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of development Diabetes Care 2001. 24:89-94.
5. DeFronzo RA. Pathogenesis of type 2 diabetes. Med Clin North Am 2004. 88:787-835.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000. 321(7258):405-412.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008. 359(15):1577-1589.
8. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007. 261:32-43.
9. Wright EM. Renal Na (+)-glucose cotransporters. Am J Physiol Renal Physiol 2001. 280(1):F10-F18.
10. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010. 5(1):133-141.
11. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008. 57:1723-1729.
12. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009. 85(5):520-526.
13. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009. 85(5):513-519.
14. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, Li T, LaCreta FP, Boulton DW. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011. 13:47-54.
15. Kasichayanula S, Liu X, Zhang W, Pfister M, Reele SB, Aubry AF, LaCreta FP, Boulton DW. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab 2011. 13(8):770-773.
16. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose co transport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009. 32(4):650-657.
17. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009. 32(9):1656-1662.
18. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010. 375(9733):2223-2233.
19. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy - efficacy of a novel insulin-independent treatment. Diabetes 2010. 59(Suppl 1):A21-A22. Abstract 78-OR.
20. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetes 2010. 59(Suppl 1). Abstract 0021-LB.
21. Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52- week results of a double-blind, randomized, controlled trial. Diabetologia 2010. 53(Suppl 1).
22. Nauck MA, et al. 0040-LB. American Diabetes Association's 71st Scientific Sessions, June 24-28, 2011, San Diego, California.
23. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabete Care 2010. 3(10):2217-2224.
24. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebocontrolled trial. Diabetes Obes Metab 2011. In press.
25. Astrazanacea-investigational compound dapagliflozin sustained glycaemic control and weight reduction. Eur Pharmaceut Rev 2011. http://www.europeanpharmaceuticalreview.com/7918/news/industry-news/bristol-myers-squibb-and-astrazenecaannounce-investigational-compound-dapagliflozinsustained-glycemic-control-and-weight-reduction-in-studyof-type2-diabetes-patients-inadequately-controlled-withme/. Accessed on Aug 1, 2011.
26. FDA briefing document NDA 202293. Advisory committee meeting July 19, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf. Accessed on Aug 5, 2011.